Every night, the online Belgian patent register ('eRegister') receives an update with public data that were entered or generated the preceding day on the Benelux Patent Platform, the computer application with which the Belgian Intellectual Property Office handles the registration, treatment and publication processes for patents and supplementary protection certificates.
Currently, some updates are spread over consecutive nights due to the large, weekly volume of data concerning European patents designating Belgium.
For a European patent it is possible that data about the inventor(s) are missing from the online Belgian patent register. They can be found via the link to the European patent register pending an update of the Belgian patent register.
For European patents with Unitary Effect, the authentic source of information is the European Patent Register : please refer to it.

Patent details

2024C522 Product name: dolutegravir of een farmaceutisch aanvaardbaar zout ervan, met inbegrip van dolutegravirnatrium, en lamivudine

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic information

Application number:
2024C/522
Type:
Certificate
SPC type:
Medical
Basic patent number:
191518976
Status:
Open & Published
Publication number:
2024C522
1rst applicant's nationality:
Procedural language:
Dutch

Marketing authorization

Marketing authorization number:
EU/1/19/1370
Marketing authorization type:
National/EU
Designates country:
No
Marketing authorization date:
03/07/2019
Marketing authorization status:
Accepted
Marketing authorization country:
Belgium (BE)

Dates

Filing date:
04/06/2024
First marketing authorization date:
03/07/2019
Grant date:
Activation date:
BE Publication date:
05/06/2024
Lapsed date:
Expiration date (if granted and all annual fees paid):
Basic SPC Expiration (if granted and all annual fees paid):
03/07/2034
SPC/SPC Extension Expiration (if granted and all annual fees paid):
03/07/2034
Rejection date:
Withdrawal date:

Applicant

Name:
VIIV Healthcare Company
Legal Form:
Private Company Limited by Shares
From:
05/06/2024
Address:
251 Little Falls Drive, 19808, Wilmington, Delaware, United States (US)
To:

Agent

Name:
DE CLERCQ & PARTNERS C.V.B.A.
Legal Form:
From:
05/06/2024
Address:
Ed. Gevaertdreef 10a, 9830, ST MARTENS LATEM, Belgium (BE)
To:

Publication

Bulletin

Bulletin heading:
SPC
Journal edition number:
2024/11
Publication date:
17/06/2024
Description:
Contains data concerning applications for- or granted Supplementary Protection Certificates

Annual fee

Annual fee(s) Due Date:
31/01/2031
Annual fee number:
21
Annual fee amount:
650 Euro
Expected payer:
Last annual fee payment date:
Last annual fee paid number:
Payer:
Filing date Document type Publication Type Document Description Number of pages File Type
04/06/2024 Application Form 4 PDF /7/0/7/3/3/0722433707/docs/2024c522_0_applicationform_20240605_084651590.pdf
05/06/2024 Publication I1 1 PDF /7/0/7/3/3/0722433707/docs/2024c522_1_i1document_20240605_105238607.pdf
04/06/2024 General Document Other 2 PDF /7/0/7/3/3/0722433707/docs/2024c522_2_generaldocument_20240605_084649507.pdf
04/06/2024 MA Official Publication Official Publication of 1st Marketing Authorization 16 PDF /7/0/7/3/3/0722433707/docs/2024c522_3_maofficialpublication_20240605_084650218.pdf
04/06/2024 Marketing Authorization 1st Marketing Authorization (EU) 3 PDF /7/0/7/3/3/0722433707/docs/2024c522_4_marketingauthorization_20240605_084649664.pdf
04/06/2024 General Document Other 4 PDF /7/0/7/3/3/0722433707/docs/2024c522_5_generaldocument_20240605_084651438.pdf
04/06/2024 Abstract Product Characteristics Abstract of the characteristics of the product 47 PDF /7/0/7/3/3/0722433707/docs/2024c522_6_abstractproductcharacteristics_20240605_084649819.pdf
04/06/2024 General Document Other 12 PDF /7/0/7/3/3/0722433707/docs/2024c522_7_generaldocument_20240605_084650390.pdf
05/06/2024 Outgoing Correspondence 2 PDF /7/0/7/3/3/0722433707/docs/2024c522_8_outgoingcorrespondence_20240605_024210558.pdf